The HER2-positive (HER2+) subtype is defined by HER2 overexpression/amplification and accounts for ~20% of breast cancers [2], 25% of ovarian cancers [3], and 18% of gastric cancers [4]. This evidence concerns the gene ERBB2 and ovarian carcinoma.